Results 271 to 280 of about 2,555,654 (307)
Some of the next articles are maybe not open access.
Current Opinion in Hematology, 1997
The molecular origin of the BCR-ABL chimeric gene is now reasonably well defined; a new breakpoint cluster region in the BCR gene, designated mu-bcr, has recently been identified. p210BCR-ABL binds with or phosphorylates a wide variety of intracellular proteins but the mechanism by which it exerts its oncogenic potential is not yet known.
openaire +2 more sources
The molecular origin of the BCR-ABL chimeric gene is now reasonably well defined; a new breakpoint cluster region in the BCR gene, designated mu-bcr, has recently been identified. p210BCR-ABL binds with or phosphorylates a wide variety of intracellular proteins but the mechanism by which it exerts its oncogenic potential is not yet known.
openaire +2 more sources
The allometry of chronic myeloid leukemia
Journal of Theoretical Biology, 2009Chronic myeloid leukemia (CML) is an acquired neoplastic hematopoietic stem cell (HSC) disorder characterized by the expression of the BCR-ABL oncoprotein. This gene product is necessary and sufficient to explain the chronic phase of CML. The only known cause of CML is radiation exposure leading to a mutation of at least one HSC, although the vast ...
Pacheco, J., Traulsen, A., Dingli, D.
openaire +3 more sources
Allografting for chronic myeloid leukemia
Current Opinion in Hematology, 1997Allogeneic stem cell transplantation is the only curative therapy for chronic myeloid leukemia. There have been several recent advances in this field. Early data suggest that blood-derived stem cells are an effective substitute for bone marrow. Allografting can be performed using progenitor cells from other family members, unrelated donors, and ...
D G, Savage, J M, Goldman
openaire +2 more sources
Splenectomy in Chronic Myeloid Leukemia
Annals of Internal Medicine, 1978We review splenectomy in chronic myeloid leukemia, emphasizing recent studies that have evaluated early splenectomy during the chronic phase of the disease. Despite current interest in splenectomy in chronic myeloid leukemia, uncontrolled clinical trials to date suggest that the operation during the early phase neither delays the onset of blastic ...
D J, Wolf, R T, Silver, M, Coleman
openaire +2 more sources
Treatment of Chronic Myeloid Leukemia
Annual Review of Medicine, 1980Most known chemotherapy agents, used singly, may induce remission of CML. Those that best alleviate symptoms (anemia, splenomegaly, etc) do not change either the Ph' chromosome anomaly in the hemopoietic cells nor the median delay of 3--4 years before fatal blastic transformation.
openaire +2 more sources
Immunotherapy of Chronic Myeloid Leukemia
2006Imatinib has become standard therapy for all phases of chronic myeloid leukemia (CML). However, data generated by monitoring several thousands of patients worldwide suggest that although imatinib is highly active against the differentiated mass of CML cells, it probably fails to eradicate all residual leukemia cells, even in the best responders.
BOCCHIA M., LAURIA F.
openaire +3 more sources
Ponatinib for Chronic Myeloid Leukemia
New England Journal of Medicine, 2012The treatment of patients with chronic myeloid leukemia (CML) must be ranked as one of the great medical success stories of the past 30 years. The demonstration that the Philadelphia (Ph) chromosome carries a fusion gene formed by the juxtaposition of BCR and ABL genetic sequences focused attention on the possibility that the tyrosine kinase activity ...
openaire +2 more sources
Leukemia Stem Cells in Chronic Myeloid Leukemia
2019Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder characterized by a chromosome translocation that generates the BCR-ABL oncogene encoding a constitutively activated tyrosine kinase. Although BCR-ABL tyrosine kinase inhibitors (TKIs) are highly effective in treating CML at chronic phase, a number of patients develop drug resistance
Yi, Shan +3 more
openaire +2 more sources